Related Experiment Video

Updated: Jun 12, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Erlotinib in the treatment of non-small cell lung cancer: current status and future developments

Cesare Gridelli1, Paolo Maione, Maria Anna Bareschino

  • 1Division of Medical Oncology, S.G. Moscati Hospital, Contrada Amoretta, Avellino, Italy. cgridelli@libero.it

Anticancer Research
|June 10, 2010
PubMed

Insights

Erlotinib effectively treats non-small cell lung cancer (NSCLC) by targeting epidermal growth factor receptor (EGFR). Identifying EGFR mutations improves treatment response prediction for NSCLC patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Erlotinib is an oral small molecule inhibitor targeting epidermal growth factor receptor (EGFR) tyrosine kinase activity.
  • It is approved for recurrent non-small cell lung cancer (NSCLC) and is under investigation for all NSCLC stages.
  • Common side effects include rash and diarrhea; the drug is generally well-tolerated.

Purpose of the Study:

  • To review the role of erlotinib in treating non-small cell lung cancer (NSCLC).
  • To discuss the importance of identifying predictive factors for optimizing erlotinib's therapeutic impact.
  • To highlight molecular characterization in identifying potentially sensitive NSCLC patients.

Main Methods:

  • Literature review on erlotinib's efficacy and safety in NSCLC.
  • Analysis of molecular characteristics associated with treatment response.
  • Discussion of predictive factors for erlotinib therapy.

Main Results:

  • Somatic mutations in the EGFR tyrosine kinase domain are linked to a high likelihood of sustained therapeutic response to erlotinib.
  • Erlotinib demonstrates tolerability with manageable toxicities.
  • Molecular characterization advances the identification of sensitive NSCLC patient populations.

Conclusions:

  • Erlotinib is a valuable therapeutic option for NSCLC.
  • Identifying EGFR mutations is crucial for predicting and enhancing treatment outcomes.
  • Further research into predictive factors will refine erlotinib's clinical application in NSCLC.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...